Evaluation of the Optilume BPH Catheter System and the Rezum Water Vapor Therapy in Treating Benign Prostatic Hyperplasia

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 9, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Benign Prostatic Hyperplasia (BPH)Lower Urinary Track Symptoms
Interventions
DEVICE

Optilume® BPH Catheter System

The technology is based on a device/drug combination consisting of two catheters: the Optilume BPH Prostatic Pre-dilation Catheter which is a non-drug coated catheter used to start commissurotomy between the lateral lobes of the prostate and the Optilume BPH Prostatic Dilatation DCB Catheter which is a drug coated catheter used to complete the commissurotomy and transfers drug (paclitaxel) to the pre-dilated prostatic urethra and anterior commissure. Hence, the device applies a mechanical dilatation to open prostatic urethral lumen to increase urine flow, followed by the transfer of paclitaxel drug to inhibit cell proliferation and maintain this dilatation.

DEVICE

Rezum Water Vapor Therapy

The Rezum system is minimally invasive therapy for LUTS secondary to BPH. The system injects water vapor at 103°C generated by radiofrequency to create thermal energy via a transurethral approach. The vapor disperses through the tissue interstices within the treatment zone (transition zone). The injection of vapor last for approximatively 9 seconds and the number of injections depends on the prostate volume and length of the prostatic urethra.

Trial Locations (1)

H2X 0A9

RECRUITING

Centre Hospitalier de l'université de Montréal (CHUM), Montreal

All Listed Sponsors
lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER